This Small-Cap Biotech is a Sneaky Play on Next-Gen Drugs

There always seems to be a “next big thing” in drug development. Selecta Life Sciences (SELB) is well positioned to ride one emerging wave.

Industry titans are showing increasing interest in an emerging therapeutic approach called immune tolerance. Investors may see it as the opposite of a vaccine. Rather than training the immune system to recognize and attack a specific molecular target, immune tolerance attempts to trick the immune system to allow certain misidentified threats to slip through its defenses.


Be the first to comment

Leave a Reply

Your email address will not be published.